From 490 Days to Market — What Has Changed
Until recently, a new medical device in Korea had to clear four stages before hospitals could use it: MFDS approval → confirmation of whether it is an existing technology → New Health Technology Assessment (nHTA) → National Health Insurance listing. Reviews and waiting times stacked up, so a company could wait up to 490 days after approval, with capital and staff tied up the whole time. For SMEs, that gap was often the hardest part to survive.
An amendment to the Rules on New Health Technology Assessment, in force since January 26, 2026, cuts this path to two stages at most for eligible items. They can reach clinical practice in as few as 80 days (typically 80–140 days) after approval. The track does not remove scrutiny, though. It moves what nHTA used to examine forward into an "enhanced clinical evaluation at an international standard" at the approval stage. The Ministry of Health and Welfare and the MFDS run the track jointly, and it only works if the company brings strong evidence at approval.
Check Eligibility First — The 199-Item List
The MFDS has announced 199 eligible items:
Eligibility depends on product classification (item name and class), not on how innovative the technology is. Confirming your exact classification code is therefore the first step. Items that are not on the list still follow the existing nHTA or deferred-assessment routes. A wrong classification can derail an entire development plan, so it is worth confirming early through an MFDS classification consultation.
The Price of Immediate Entry — Heavier Clinical Design at Approval
The biggest change falls on approval-stage clinical studies. The standard for comparators, endpoints and efficacy evidence now effectively matches nHTA.
The Real Test Comes After Entry — Use Period and Reassessment
Technologies that enter through this track are reassessed after a set period of clinical use. Check the exact period and requirements against the official notices and announcements. Weak evidence at reassessment can make continued use difficult, so plan the following before entry:
Nine Months In — What the Field Shows
Companies on the same track are seeing different results. The gap usually comes down to three factors: whether the item is on the list, whether the approval-stage evidence is strong enough, and whether hospitals actually want to adopt it.
It is easy to miss that market entry and reimbursement or sales channels are separate problems. Faster entry does not become revenue unless hospitals have a clear reason to use the product and a workable cost structure. Without a sales strategy, the time saved has limited value.
Action Checklist for SME Device Makers
Making full use of MFDS pre-submission consultations and product commercialization support programs can save a great deal of trial and error along the way.
KITIM helps medical device companies build regulatory roadmaps, design clinical strategies and connect with government R&D and clinical support programs. If you are unsure whether your product qualifies for immediate entry or how to strengthen your approval-stage evidence, contact KITIM. We will work with you on a market-entry strategy that fits your product's stage.
